Margaret Frame is Professor of Cancer Biology and Science Director of Cancer Research Centre at the University of Edinburgh. She is also Director of MRC Institute of Genetics & Molecular Medicine. She has made seminal contributions to understanding mechanisms of cell adhesion and motility. She previously served as deputy-director of the Beatson Institute in Glasgow. Education Frame graduated with a first class honours BSc in Biochemistry, followed by a PhD from the Medical Faculty, at the University of Glasgow. Career Margaret Frame worked for a brief period in industry, before joining the MRC Virology Unit in Glasgow as a post-doctoral scientist. In 1991 she started work at the Beatson Institute for Cancer Research, first as a post-doc and subsequently as a group leader. In 1995, she was jointly appointed as Professor of Cancer Research in the Faculty of Biological Sciences at the University of Glasgow and the Beatson Institute, where she became Deputy Director in 2002. In October 2007 she joined the new MRC-University of Edinburgh Institute of Genetics and Molecular Medicine. She co-directs the Edinburgh Cancer Research Centre in Edinburgh University’s College of Medicine and Veterinary Medicine, with the role of Science Director in the Cancer Research UK Centre (established January 2010). The vision of the Edinburgh Cancer Research Centre is to develop novel and emerging technologies for the development of innovative cancer discovery and translational science. Together with colleagues, she formed the Edinburgh Cancer Discovery Unit, which aims to generate evidence-led tests for cancer therapeutics and combinations that will predict clinical efficacy. Research Margaret Frame’s long-held research interests are in cancer invasion and metastasis, and the role of tyrosine kinases in controlling tumour cell spread. She has had several CR-UK funded programs of research to work on understanding cancer invasion and metastasis and was awarded a European Research Council Advanced Investigator grant to build a novel cancer discovery platform. Her main goal is to work with clinicians treating cancers of unmet need, to determine whether targeting the invasive and metastatic processes may be of therapeutic benefit, and may be monitored in the preclinical and clinical settings by novel imaging techniques. Her research group works on cell adhesion networks in cancer, with specific focus on the regulation and role of the adhesion-linked ‘nodal’ Tyrosine Kinases, and their extensive network of interacting partners. In particular Src and FAK kinases reside at sites of cell interaction with the environment or neighbouring